Gilead SciencesGILD

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer.

Ratings

3 / 5

3 ratings in the last 12 months

5
4
3
2
1
CEO
Mr. Daniel O’Day

$79.1B

Market Cap • 13/06/2024

1987

(há 37 anos)
Fundação

1992

(32 years ago)
IPO

NASDAQ

Listagem

S&P500 Participant

Index Composite • 2024
Flag of US

Foster

Sede • California

17.000

N° de Empregados • 2022

Valuation

Valuation Indicators

Retorno Histórico

GILDSó no Premium...

Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.

0%

1 dia

11/06/2024

1%

1 semana

07/06/2024

-4%

1 mês

14/05/2024

-17%

1 ano

14/06/2023

-2%

5 anos

14/06/2019

10 anos

Histórico